Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 25, 2023

BP Elements

  • BioPharm International's BP Elements, May 2023
  • Volume 2
  • Issue 5

JMI Laboratories and bioMérieux Enter Antimicrobial Resistance Diagnostics Partnership

Author(s)Grant Playter

JMI Laboratories and bioMérieux will work to improve microbiology diagnostics tools.

JMI Laboratories, a microbiology laboratory owned by Element Materials Technology, and bioMérieux, a French biotechnology company specializing in diagnostics, announced a six-year partnership in an April 20, 2023 press release. The collaboration will aim to improve microbiology diagnostics in tools to fight antimicrobial resistance (AMR).

According to a company press release, Antimicrobial Stewardship Programs are dependent on rapid, reliable testing that must be continuously evaluated against new and emerging strains of global pathogens. In this partnership, bioMérieux will use data collected through JMI’s microbial surveillance tools to continuously assess AMR results.

“We are excited to partner with bioMérieux on these projects as we appreciate their commitment to improving patient care by providing accurate microbial identification and antimicrobial susceptibility testing results,” said Mariana Castanheira, chief scientific officer of JMI Labs, in the press release. “Our scientists look forward to managing these studies testing challenging organisms, including those carrying important mechanisms of resistance.”

“Through our combined efforts, we can proactively alert the scientific community of potential growing threats and effectively steer antimicrobial research and development,” said François Lacoste, executive vice-president, Research & Development, bioMérieux, in the release.

Source: bioMérieux


Related to this article

The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.